Infant drugs company struggles

The drugs company, Actelion, said on Thursday that its third quarter loss widened to SFr11.7 million ($6.6 million). Its losses for the same period in 1999 amounted to SFr3.5 million.

This content was published on November 9, 2000 - 09:58

But the management said the figures were in line with expectations.

The company has yet to launch its first product. It expects to begin selling the hypertension drug, Tracleer, in the second half of next year pending approval from the United States Food and Drug Administration.

Actelion is listed on the high-tech SWX New Market and its management team is made up largely of former Roche employees.

swissinfo with agencies

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Change your password

Do you really want to delete your profile?